Withaferin A Inhibits Neutrophil Adhesion, Migration, and Respiratory Burst and Promotes Timely Neutrophil Apoptosis.
Authors: Bayless Rosemary L, Sheats M Katie, Jones Samuel L
Journal: Frontiers in veterinary science
Summary
Neutrophil-driven inflammation underpins several economically significant equine conditions—notably recurrent airway obstruction, laminitis, and post-ischaemic intestinal injury—making strategies to dampen neutrophil activity a compelling therapeutic avenue. Bayless and colleagues investigated withaferin A (WFA), a plant-derived compound with documented anti-inflammatory activity, testing whether it could suppress equine neutrophil adhesion, migration, and oxidative burst whilst simultaneously accelerating apoptosis in primed cells. The researchers demonstrated that WFA produced concentration-dependent reductions across all three functional parameters—a meaningful finding given that each represents a distinct mechanism by which neutrophils perpetuate tissue damage. Notably, the pro-apoptotic effect was selective, occurring only in granulocyte-macrophage colony-stimulating factor–primed neutrophils over 24 hours and not in resting cells, which has practical implications for avoiding inadvertent suppression of protective immunity during acute infection. Although further work is required to characterise the molecular pathways involved and establish clinical efficacy in vivo, these results suggest WFA warrants investigation as a potential modulator of pathological neutrophil-mediated inflammation in horses, particularly for chronic conditions where controlled apoptosis might reduce tissue injury without compromising immediate immune function.
Read the full abstract on PubMed
Practical Takeaways
- •Withaferin A shows promise as a potential therapeutic agent for equine conditions involving excessive neutrophilic inflammation (asthma, laminitis, ischemia-reperfusion injury), though clinical efficacy in horses has not yet been demonstrated
- •This is foundational in vitro research; significant additional work needed to determine optimal dosing, bioavailability, and safety in live horses before clinical application
- •Consider monitoring emerging research on WFA as a potential adjunctive anti-inflammatory therapy, but do not use clinically in horses until in vivo and clinical trials are completed
Key Findings
- •Withaferin A (WFA) caused concentration-dependent inhibition of equine neutrophil adhesion, migration, and respiratory burst in response to diverse stimuli
- •WFA treatment increased apoptosis of equine neutrophils exposed to GM-CSF for 24 hours
- •Pro-apoptotic effect of WFA was specific to primed neutrophils and not observed in unprimed neutrophils at 2-hour timepoint
- •WFA may reduce neutrophil-mediated inflammation through multiple mechanisms including suppression of inflammatory responses and promotion of apoptosis